Last 12 months
Inside the activity.
2 purchase rows · 30 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 2 | 3 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 7 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2017 Filed Sep 13, 2017 22:38 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
Disposition to issuerCommon Stock | 3,964 | $71.81 | $284,668.32 |
DisclosureSEC source: 0001093557-17-000198 · edgardoc.xml · nonDerivative · entry 2 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,776 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 54,010 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:38 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
Disposition to issuerCommon Stock | 3,347 | $71.81 | $240,359.45 |
DisclosureSEC source: 0001093557-17-000198 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,740 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 54,010 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:37 UTC |
Murphy Patrick MichaelVP, Legal Aff & Chf Compl Ofcr
|
Disposition to issuerCommon Stock | 1,322 | $71.81 | $94,937.31 |
DisclosureSEC source: 0001093557-17-000197 · edgardoc.xml · nonDerivative · entry 1 Murphy Patrick Michael · CIK 0001692785 · VP, Legal Aff & Chf Compl Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,131 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 23,092 unvested restricted stock units, 11,361 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 7,500 of which were granted on March 8, 2016 shall vest through March 8, 2019 and 4,231 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:36 UTC |
MOY JEFFREYSVP, Operations
|
Disposition to issuerCommon Stock | 3,523 | $71.81 | $252,998.61 |
DisclosureSEC source: 0001093557-17-000196 · edgardoc.xml · nonDerivative · entry 6 MOY JEFFREY · CIK 0001446422 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 70,400 F4 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F3 · balance_after: Shares are held by the Moy Family Trust U/A/D 12/09/2013, with respect to which the reporting person is a trustee. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:36 UTC |
MOY JEFFREYSVP, Operations
|
Disposition to issuerCommon Stock | 2,907 | $71.81 | $208,761.55 |
DisclosureSEC source: 0001093557-17-000196 · edgardoc.xml · nonDerivative · entry 5 MOY JEFFREY · CIK 0001446422 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 73,923 F4 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F3 · balance_after: Shares are held by the Moy Family Trust U/A/D 12/09/2013, with respect to which the reporting person is a trustee. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:36 UTC |
MOY JEFFREYSVP, Operations
|
OtherCommon Stock | 6,666 | $71.26 | $475,019.16 |
DisclosureSEC source: 0001093557-17-000196 · edgardoc.xml · nonDerivative · entry 4 MOY JEFFREY · CIK 0001446422 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 76,830 F1 · shares: Shares were transferred from direct ownership to ownership under the Moy Family Trust upon vesting of previously awarded restricted stock units. F3 · balance_after: Shares are held by the Moy Family Trust U/A/D 12/09/2013, with respect to which the reporting person is a trustee. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:36 UTC |
MOY JEFFREYSVP, Operations
|
OtherCommon Stock | 5,500 | $71.26 | $391,930.00 |
DisclosureSEC source: 0001093557-17-000196 · edgardoc.xml · nonDerivative · entry 3 MOY JEFFREY · CIK 0001446422 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 70,164 F1 · shares: Shares were transferred from direct ownership to ownership under the Moy Family Trust upon vesting of previously awarded restricted stock units. F3 · balance_after: Shares are held by the Moy Family Trust U/A/D 12/09/2013, with respect to which the reporting person is a trustee. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:36 UTC |
MOY JEFFREYSVP, Operations
|
OtherCommon Stock | 6,666 | $71.26 | $475,019.16 |
DisclosureSEC source: 0001093557-17-000196 · edgardoc.xml · nonDerivative · entry 2 MOY JEFFREY · CIK 0001446422 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,410 F1 · shares: Shares were transferred from direct ownership to ownership under the Moy Family Trust upon vesting of previously awarded restricted stock units. F2 · balance_after: Included in this number are 45,050 unvested restricted stock units, 21,883 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 16,500 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 6,667 of which were granted on March 8, 2015 and shall vest through March 08, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:36 UTC |
MOY JEFFREYSVP, Operations
|
OtherCommon Stock | 5,500 | $71.26 | $391,930.00 |
DisclosureSEC source: 0001093557-17-000196 · edgardoc.xml · nonDerivative · entry 1 MOY JEFFREY · CIK 0001446422 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,076 F1 · shares: Shares were transferred from direct ownership to ownership under the Moy Family Trust upon vesting of previously awarded restricted stock units. F2 · balance_after: Included in this number are 45,050 unvested restricted stock units, 21,883 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 16,500 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 6,667 of which were granted on March 8, 2015 and shall vest through March 08, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:23 UTC |
Leach Jacob StevenSVP, Research & Development
|
Disposition to issuerCommon Stock | 2,819 | $71.81 | $202,441.97 |
DisclosureSEC source: 0001093557-17-000191 · edgardoc.xml · nonDerivative · entry 2 Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,919 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 45,801 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 16,000 of which were granted on March 8, 2016 shall vest through March 8, 2019 and 6,667 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:23 UTC |
Leach Jacob StevenSVP, Research & Development
|
Disposition to issuerCommon Stock | 3,523 | $71.81 | $252,998.61 |
DisclosureSEC source: 0001093557-17-000191 · edgardoc.xml · nonDerivative · entry 1 Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,738 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 45,801 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 16,000 of which were granted on March 8, 2016 shall vest through March 8, 2019 and 6,667 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:23 UTC |
Balo Andrew KEVP, Reg. Strategy, Clinical
|
Disposition to issuerCommon Stock | 3,347 | $71.81 | $240,359.45 |
DisclosureSEC source: 0001093557-17-000190 · edgardoc.xml · nonDerivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,282 F4 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F3 · balance_after: Included in this number are 55,678 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:23 UTC |
Balo Andrew KEVP, Reg. Strategy, Clinical
|
Disposition to issuerCommon Stock | 4,184 | $71.81 | $300,467.27 |
DisclosureSEC source: 0001093557-17-000190 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,629 F4 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F3 · balance_after: Included in this number are 55,678 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:23 UTC |
Balo Andrew KEVP, Reg. Strategy, Clinical
|
SaleCommon Stock | 3,244 | $72.27 | $234,441.28 |
DisclosureSEC source: 0001093557-17-000190 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,813 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.81 to $72.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 55,678 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:22 UTC |
DOUBLEDAY RICHARDEVP, Chief Commercial Officer
|
Disposition to issuerCommon Stock | 4,184 | $71.81 | $300,467.27 |
DisclosureSEC source: 0001093557-17-000189 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,049 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 54,427 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:22 UTC |
DOUBLEDAY RICHARDEVP, Chief Commercial Officer
|
Disposition to issuerCommon Stock | 3,347 | $71.81 | $240,359.45 |
DisclosureSEC source: 0001093557-17-000189 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,233 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 54,427 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 23:47 UTC |
Blackford Quentin S.EVP, CFO, PFO & PAO
|
GrantCommon Stock | 62,358 | $0.00 | $62.36 |
DisclosureSEC source: 0001093557-17-000185 · edgardoc.xml · nonDerivative · entry 1 Blackford Quentin S. · CIK 0001612451 · EVP, CFO, PFO & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,756 F1 · shares: Represents a grant of restricted stock units that shall vest in four equal annual installments on September 7, 2018, September 7, 2019, September 7, 2020 and September 7, 2021. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 62,358 unvested restricted stock units which were granted on September 7, 2017 and shall vest through September 7, 2021. Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 23:31 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
SaleCommon Stock | 3,987 | $75.26 | $300,044.87 |
DisclosureSEC source: 0001093557-17-000181 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,087 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.98 to $75.62. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 23:31 UTC |
DOUBLEDAY RICHARDEVP, Chief Commercial Officer
|
SaleCommon Stock | 1,635 | $75.26 | $123,052.88 |
DisclosureSEC source: 0001093557-17-000180 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 23,785 F1 · shares: On May 16, 2017 Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.99 to $75.58. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 23:31 UTC |
ACE HEATHER SSVP Human Resources
|
Disposition to issuerCommon Stock | 2,617 | $75.33 | $197,144.89 |
DisclosureSEC source: 0001093557-17-000179 · edgardoc.xml · nonDerivative · entry 1 ACE HEATHER S · CIK 0001610762 · SVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,766 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 42,508 unvested restricted stock units, 21,883 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 20,625 of which were granted on August 22, 2016 and shall vest through August 22, 2020. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 21:52 UTC |
SAYER KEVIN RDirector · President & CEO
|
SaleCommon Stock | 6,000 | $69.77 | $418,636.80 |
DisclosureSEC source: 0001093557-17-000175 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,680 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.63 to $70.03. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 21:54 UTC |
Balo Andrew KEVP, Reg. Strategy, Clinical
|
SaleCommon Stock | 3,244 | $71.18 | $230,921.22 |
DisclosureSEC source: 0001093557-17-000173 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,989 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.00 to $71.37. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 00:55 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
SaleCommon Stock | 1,450 | $69.47 | $100,724.69 |
DisclosureSEC source: 0001093557-17-000163 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,074 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.38 to $69.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| July 12, 2017 Filed Jul 12, 2017 21:33 UTC |
SAYER KEVIN RDirector · President & CEO
|
SaleCommon Stock | 6,000 | $71.86 | $431,174.40 |
DisclosureSEC source: 0001093557-17-000161 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,680 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.31 to $72.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 21:32 UTC |
Balo Andrew KEVP, Reg. Strategy, Clinical
|
SaleCommon Stock | 3,200 | $71.55 | $228,972.48 |
DisclosureSEC source: 0001093557-17-000160 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Reg. Strategy, Clinical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,233 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.00 to $72.20. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 22:56 UTC |
DOUBLEDAY RICHARDEVP, Chief Commercial Officer
|
SaleCommon Stock | 3,187 | $78.22 | $249,272.80 |
DisclosureSEC source: 0001093557-17-000157 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 25,420 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.65 to $78.90. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| June 23, 2017 Filed Jun 27, 2017 22:55 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
SaleCommon Stock | 1,450 | $78.19 | $113,377.53 |
DisclosureSEC source: 0001093557-17-000156 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,524 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.77 to $78.90. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:27 UTC |
Balo Andrew KEVP, Clinical and Regulatory
|
SaleCommon Stock | 3,200 | $69.06 | $220,988.80 |
DisclosureSEC source: 0001093557-17-000153 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,433 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $68.50 to $69.60. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:26 UTC |
SAYER KEVIN RDirector · President & CEO
|
SaleCommon Stock | 6,000 | $69.07 | $414,411.00 |
DisclosureSEC source: 0001093557-17-000152 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,680 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $68.49 to $69.60. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 00:50 UTC |
SKYLER JAY SDirector
|
GrantCommon Stock | 4,553 | $0.00 | $4.55 |
DisclosureSEC source: 0001093557-17-000149 · edgardoc.xml · nonDerivative · entry 1 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,553 F1 · shares: Share units are restricted and subject to vesting in one annual installment from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 00:50 UTC |
KAHN BARBARADirector
|
GrantCommon Stock | 4,353 | $0.00 | $4.35 |
DisclosureSEC source: 0001093557-17-000148 · edgardoc.xml · nonDerivative · entry 1 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,353 F1 · shares: Share units are restricted and subject to vesting in one annual installment from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 00:49 UTC |
AUGUSTINOS NICHOLASDirector
|
GrantCommon Stock | 4,353 | $0.00 | $4.35 |
DisclosureSEC source: 0001093557-17-000147 · edgardoc.xml · nonDerivative · entry 1 AUGUSTINOS NICHOLAS · CIK 0001238485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,015 F1 · shares: Share units are restricted and subject to vesting in one annual installment from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 4,353 unvested restricted stock units which were granted on June 1, 2017 and shall vest on June 1, 2018. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 00:48 UTC |
FOLETTA MARK GDirector
|
GrantCommon Stock | 4,952 | $0.00 | $4.95 |
DisclosureSEC source: 0001093557-17-000146 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,595 F1 · shares: Share units are restricted and subject to vesting in one annual installment from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 7,240 unvested restricted stock units, 4,952 of which were granted on June 1, 2017 and shall vest on June 1, 2018 and 2,288 of which were granted on November 17, 2014 and shall vest through November 17, 2017. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 00:48 UTC |
Collins Richard AlexanderDirector
|
GrantCommon Stock | 4,353 | $0.00 | $4.35 |
DisclosureSEC source: 0001093557-17-000145 · edgardoc.xml · nonDerivative · entry 2 Collins Richard Alexander · CIK 0001700619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,855 F1 · shares: Share units are restricted and subject to vesting in one annual installment from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 5,355 unvested restricted stock units which were granted on June 1, 2017 and shall vest on June 1, 2018. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 00:48 UTC |
Collins Richard AlexanderDirector
|
GrantCommon Stock | 1,002 | $0.00 | $1.00 |
DisclosureSEC source: 0001093557-17-000145 · edgardoc.xml · nonDerivative · entry 1 Collins Richard Alexander · CIK 0001700619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,502 F1 · shares: Share units are restricted and subject to vesting in one annual installment from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 5,355 unvested restricted stock units which were granted on June 1, 2017 and shall vest on June 1, 2018. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 00:47 UTC |
ALTMAN STEVEN RDirector
|
GrantCommon Stock | 4,353 | $0.00 | $4.35 |
DisclosureSEC source: 0001093557-17-000144 · edgardoc.xml · nonDerivative · entry 1 ALTMAN STEVEN R · CIK 0001191307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,353 F1 · shares: Share units are restricted and subject to vesting in one annual installment from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 00:47 UTC |
TOPOL ERICDirector
|
GrantCommon Stock | 4,653 | $0.00 | $4.65 |
DisclosureSEC source: 0001093557-17-000143 · edgardoc.xml · nonDerivative · entry 1 TOPOL ERIC · CIK 0001468345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,653 F1 · shares: Share units are restricted and subject to vesting in one annual installment from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 00:02 UTC |
Abbey DonaldEVP Quality
|
Disposition to issuerCommon Stock | 7,784 | $66.38 | $516,706.59 |
DisclosureSEC source: 0001093557-17-000135 · edgardoc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · EVP Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,726 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 64,176 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 36,666 of which were granted on May 31, 2016 and shall vest through May 31, 2019. Read SEC document |
| May 24, 2017 Filed May 26, 2017 20:24 UTC |
GREGG TERRANCE HDirector · Executive Chairman
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.85 | $0.00 |
DisclosureSEC source: 0001093557-17-000131 · edgardoc.xml · derivative · entry 4 GREGG TERRANCE H · CIK 0001236388 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2017-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2017 Filed May 26, 2017 20:24 UTC |
GREGG TERRANCE HDirector · Executive Chairman
|
Exercise / conversionCommon Stock | 30,000 | $6.85 | $205,500.00 |
DisclosureSEC source: 0001093557-17-000131 · edgardoc.xml · nonDerivative · entry 1 GREGG TERRANCE H · CIK 0001236388 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Included in this number are 30,877 unvested restricted stock units which were granted on March 8, 2017 and shall vest on March 8, 2018. Read SEC document |
| May 23, 2017 Filed May 25, 2017 23:16 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
SaleCommon Stock | 1,450 | $68.24 | $98,949.02 |
DisclosureSEC source: 0001093557-17-000129 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,974 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.98 to $68.87. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| May 23, 2017 Filed May 25, 2017 23:15 UTC |
DOUBLEDAY RICHARDEVP, Chief Commercial Officer
|
SaleCommon Stock | 3,182 | $68.29 | $217,290.19 |
DisclosureSEC source: 0001093557-17-000128 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 28,607 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.92 to $69.06. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| May 17, 2017 Filed May 18, 2017 21:46 UTC |
SAYER KEVIN RDirector · President & CEO
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,649 | $68.40 Strike: $8.79 | $249,599.99 |
DisclosureSEC source: 0001093557-17-000125 · edgardoc.xml · derivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,649 shares Expires 2017-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2017 Filed May 18, 2017 21:46 UTC |
SAYER KEVIN RDirector · President & CEO
|
SaleCommon Stock | 5,000 | $68.39 | $341,925.00 |
DisclosureSEC source: 0001093557-17-000125 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,680 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $67.86 to $68.89. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| May 17, 2017 Filed May 18, 2017 21:46 UTC |
SAYER KEVIN RDirector · President & CEO
|
SaleCommon Stock | 3,649 | $68.40 | $249,599.99 |
DisclosureSEC source: 0001093557-17-000125 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,680 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.86 to $69.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| May 17, 2017 Filed May 18, 2017 21:46 UTC |
SAYER KEVIN RDirector · President & CEO
|
Exercise / conversionCommon Stock | 3,649 | $8.79 | $32,074.71 |
DisclosureSEC source: 0001093557-17-000125 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2017 Filed May 17, 2017 23:36 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-17-000123 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,424 F1 · shares: This transaction represents a gift of securities made by the reporting person. This is not a market transaction, thus no price has been reported. Transferor retains no beneficial or voting interest in the transferred shares. F2 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| May 10, 2017 Filed May 12, 2017 22:19 UTC |
Balo Andrew KEVP, Clinical and Regulatory
|
SaleCommon Stock | 3,200 | $71.93 | $230,176.00 |
DisclosureSEC source: 0001093557-17-000121 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,633 F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 23:04 UTC |
Pacelli Steven RobertEVP, Strategy & Corp. Dev.
|
SaleCommon Stock | 1,450 | $75.89 | $110,040.94 |
DisclosureSEC source: 0001093557-17-000107 · edgardoc.xml · nonDerivative · entry 1 Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,424 F1 · shares: On December 06, 2016 Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.60 to $76.11. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2019. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 23:04 UTC |
DOUBLEDAY RICHARDEVP, Chief Commercial Officer
|
SaleCommon Stock | 3,182 | $75.78 | $241,131.01 |
DisclosureSEC source: 0001093557-17-000106 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,369 F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.33 to $76.19. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.